...
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >The contribution of molecular epidemiology to the identification of human carcinogens: Current status and future perspectives
【24h】

The contribution of molecular epidemiology to the identification of human carcinogens: Current status and future perspectives

机译:分子流行病学对人类致癌物鉴定的贡献:现状和未来展望

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: The use of biological-based markers of exposure, intermediate effect, outcome, and susceptibility has become standard practice in cancer epidemiology, which has contributed to identification of several carcinogenic agents. Nevertheless, with the exception of biological agents, this contribution, in terms of providing sufficiently strong evidence as required by the International Agency for Research on Cancer (IARC) monographs, has been modest. Materials and methods: We discuss the overall contribution of molecular epidemiology to identification of carcinogens, with focus on IARC monographs. Results: For many carcinogens, valid biological markers of exposure and mechanisms of actions are not available. Molecular markers are usually assessed in single biological samples, which may not represent the actual exposure or biological events related to carcinogens. The contribution of molecular epidemiology to identification of carcinogens has mainly been limited to the carcinogens acting through a genotoxic mechanism, i.e. when carcinogens induce DNA damage. A number of factors, including certain hormones and overweight/obesity, may show carcinogenic effects through nongenotoxic pathways, for which mechanisms of carcinogenicity are not well identified and their biomarkers are sparse. Conclusion: Longitudinal assessment of biomarkers may provide more informative data in molecular epidemiology studies. For many carcinogens and mechanistic pathways, in particular nongenotoxic carcinogenicity, valid biological markers still need to be identified.
机译:背景:使用基于生物学的暴露,中间作用,结果和药敏性标志物已成为癌症流行病学的标准做法,这有助于鉴定几种致癌剂。但是,除了生物制剂外,在提供国际癌症研究机构(IARC)专着所要求的足够有力的证据方面,这种贡献是微不足道的。材料和方法:我们讨论分子流行病学对致癌物鉴定的总体贡献,重点是IARC专着。结果:对于许多致癌物,没有有效的暴露生物标志物和作用机理。分子标记通常在单个生物样品中评估,可能无法代表与致癌物有关的实际暴露或生物学事件。分子流行病学对致癌物鉴定的贡献主要限于通过遗传毒性机制起作用的致癌物,即致癌物诱导DNA损伤时。许多因素,包括某些激素和超重/肥胖症,可能通过非遗传毒性途径显示出致癌作用,而其致癌性机制尚不明确,其生物标志物稀疏。结论:对生物标志物的纵向评估可能会在分子流行病学研究中提供更多信息。对于许多致癌物和机制途径,特别是非遗传毒性致癌性,仍然需要确定有效的生物学标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号